Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

NCT04779554 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Carcinomatosis

Interventions

DRUG: Mitomycin C, flat dose 40 mg
DRUG: Mitomycin C, weight-based dose 12.5 mg/m2

Sponsor

Prakash Pandalai